NCT00307749View on ClinicalTrials.gov

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

August 31, 2007

Conditions
Diabetic Polyneuropathy
Interventions
DRUG

Placebo

once daily for 24 weeks

DRUG

MCC-257

20mg, once daily for 24 weeks

DRUG

MCC-257

40mg, once daily for 24 weeks

DRUG

MCC-257

80mg, once daily for 24 weeks

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY